

Development of Surface-FIDA towards a diagnostic tool for Alzheimer's disease

Lei Wang-Dietrich

Forschungszentrum Jülich GmbH
Institute of Complex Systems (ICS)
Strukturbiochemie (ICS-6)

Development of Surface-FIDA towards a diagnostic tool for Alzheimer's disease

Lei Wang-Dietrich

Schriften des Forschungszentrums Jülich
Reihe Gesundheit / Health

Band / Volume 55

ISSN 1866-1785


ISBN 978-3-89336-801-3

Table of contents

List of figures	IV
List of tables	VI
1 INTRODUCTION	1
1.1 Alzheimer's disease.....	1
1.1.1 Alzheimer's disease overview.....	1
1.1.2 Neuropathology and neurobiology of Alzheimer's disease	2
1.2 Amyloid- β	4
1.2.1 Amyloid precursor protein	5
1.2.2 Isoforms of A β	6
1.2.3 Aggregate states of A β	7
1.2.4 Amyloid cascade hypothesis	8
1.3 Diagnosis of Alzheimer's disease	11
1.3.1 Brain imaging in clinical trials	11
1.3.2 Biomarkers of Alzheimer's disease.....	12
1.3.3 Biological diagnosis of Alzheimer's disease	13
1.3.4 Surface-fluorescence intensity distribution analysis to detect protein aggregates in body fluids.....	15
1.4 Aim of this work	18
2 MATERIALS AND METHODS.....	19
2.1 Materials.....	19
2.1.1 Chemicals.....	19
2.1.2 Peptides	20
2.1.3 Antibodies	20
2.1.4 Buffers	21
2.1.5 Kits	21
2.1.6 Materials and apparatus.....	22

2.2	Methods.....	24
2.2.1	Microtiter plates	24
2.2.2	Preparation of synthetic A β aggregates.....	25
2.2.3	Preparation of synthetic A β oligomers and monomers using size exclusion chromatography.....	26
2.2.4	Fluorescence labeling of antibodies	27
2.2.5	Non-covalent immobilization of A β aggregates to glass surfaces	28
2.2.6	Procedure of immobilization of A β multimers using CMD as spacer on the glass surface	29
2.2.7	Immobilization of carboxymethyl dextran.....	29
2.2.7.1	<i>Preparation of glass surface coated with carboxymethyl dextran</i>	29
2.2.7.2	<i>X-ray photoelectron spectroscopy (XPS) analysis</i>	30
2.2.8	Covalent immobilization of capture antibodies using CMD as spacer	31
2.2.9	Immobilization of A β multimers to CMD modified glass surfaces using covalent attachment	32
2.2.10	Single A β detection and data acquisition	32
2.2.11	Surface-FIDA measurements of human CSF samples.....	34
3	RESULTS.....	36
3.1	Adaption of Surface-FIDA to LSM	36
3.1.1	Determination of optimal measurement distance to the glass surface	36
3.2	Investigation of A β isoforms in heterogeneous aggregates	39
3.2.1	Specificity of C-terminal antibodies in Surface-FIDA	40
3.2.2	Detection of A β isoforms in heterogeneous aggregates (A β 1-40/A β 1-42)	42
3.2.3	Preparation and detection of A β isoforms in heterogeneous oligomers (A β 1-40/A β 1-42).....	49
3.2.4	Detection of A β isoforms in heterogeneous aggregates (A β pGlu3-42 with A β 1-40/A β 1-42).....	51
3.3	Carboxymethyl dextran immobilization of capture antibodies on the glass surface.....	53
3.3.1	Immobilization of carboxymethyl dextran on the glass surface	54
3.3.2	Homogeneity of CMD coated surface.....	56
3.4	Comparison of poly-D-lysine and carboxymethyl dextran coated surfaces	56

3.5	Detection of synthetic A β oligomers.....	58
3.5.1	Distinguishing of synthetic A β oligomers from monomers by the Surface-FIDA	58
3.5.2	Correlation of A β oligomer concentration with readout	60
3.6	Application of Surface-FIDA using human CSF samples	61
3.6.1	Refinement of analysis.....	62
3.6.1.1	<i>Scan area</i>	63
3.6.1.2	<i>Pixels and fluorescence intensities</i>	64
3.6.1.3	<i>Analysis parameter: cut-off and rolling ball</i>	65
3.6.2	Surface-FIDA as a diagnostic assay for AD	68
3.6.2.1	<i>Study 1: CSF samples of 6 patients and 6 controls</i>	68
3.6.2.2	<i>Study 2: Measurement of 40 CSF samples</i>	68
3.6.2.3	<i>Study 3: Reproducibility of the assay</i>	69
3.6.3	Correlation of mini-mental state examination and age with Surface-FIDA readout	70
4	DISCUSSION.....	72
4.1	Optimized Surface-FIDA is able to detect single A β aggregates.....	73
4.2	Surface-FIDA is able to determine the isoform composition of heterogeneous aggregates.....	79
4.3	Surface-FIDA has a high sensitivity to detect A β oligomers.....	80
4.4	The challenge: Surface-FIDA is able to distinguish CSF samples of AD affected patients from CSF of healthy controls.....	82
4.5	Future prospect.....	85
5	SUMMARY.....	86
6	ZUSAMMENFASSUNG.....	87
ABBREVIATIONS		89
REFERENCE		91
EIDESSTATTLICHE ERKLÄRUNG.....		102
ACKNOWLEDGEMENT		103



Gesundheit / Health
Band / Volume 55
ISBN 978-3-89336-801-3

 **JÜLICH**
FORSCHUNGSZENTRUM